title: 6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats.
abstract: The effect of a unilateral 6-hydroxydopamine (6-OHDA) lesion and/or repeated administration of levodopa (L-DOPA) to normal and 6-OHDA-lesioned rats on alpha-synuclein mRNA expression was investigated by in situ hybridization histochemistry. A 6-OHDA lesion of the nigro-striatal pathway alone, confirmed by the loss of nigral tyrosine hydroxylase mRNA expression, markedly decreased alpha-synuclein mRNA in the lesioned substantia nigra (SN). In contrast, the levels of alpha-synuclein mRNA in the denervated striatum and nucleus accumbens were not altered. Chronic administration of L-DOPA to normal or 6-OHDA-lesioned rats had no effect on alpha-synuclein mRNA expression in the SN, striatum or nucleus accumbens. These data confirm that alpha-synuclein is localized in the nigro-striatal tract but that its gene expression is not regulated by dopamine.
authors.affiliation: Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King's College, London SE1 1UL, UK.
authors.forename: B-Y
authors.initials: BY
authors.lastname: Zeng
authors.forename: B
authors.initials: B
authors.lastname: Dass
authors.forename: A
authors.initials: A
authors.lastname: Owen
authors.forename: S
authors.initials: S
authors.lastname: Rose
authors.forename: C
authors.initials: C
authors.lastname: Cannizzaro
authors.forename: B C
authors.initials: BC
authors.lastname: Tel
authors.forename: P
authors.initials: P
authors.lastname: Jenner
mesh_terms: D000818:Animals; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents / Q000494:pharmacology; D004334:Drug Administration Schedule; D008297:Male; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000235:genetics*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D016627:Oxidopamine / Q000494:pharmacology; D010300:Parkinson Disease / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D012333:RNA, Messenger / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*; D013565:Sympatholytics / Q000494:pharmacology; D051843:Synucleins; D014446:Tyrosine 3-Monooxygenase / Q000187:drug effects / Q000378:metabolism; D051844:alpha-Synuclein
chemical_list: D015259:Dopamine Agents; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; C497606:Snca protein, rat; D013565:Sympatholytics; D051843:Synucleins; D051844:alpha-Synuclein; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine